Skip to Content

EHA 2019: Three-year data from the DALIAH trial: Recombinant interferon alpha-2 VS hydroxyurea in patients with myeloproliferative neoplasms

Get access to the article

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top